Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
GENOPTIC vs NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Gramicidin is a polypeptide antibiotic that increases cell membrane permeability by forming ion channels, leading to bacterial cell death.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
Instill 2 drops (or appropriate amount) into affected eye(s) every 2-4 hours for 7-10 days. Frequency may be increased to every 1-2 hours in severe infections. Ophthalmic suspension, not for injection.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Neomycin: 2-3 hours (normal renal function); polymyxin B: 6-8 hours; gramicidin: ~10 hours (estimated from topical absorption). Prolonged in renal impairment, especially for polymyxin B.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal: ~95% for neomycin (unchanged), minimal for polymyxin B (1-10% unchanged) and gramicidin (<1%). Fecal: 50-60% for polymyxin B (biliary), ~1% for neomycin.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic